Acumen Pharmaceuticals(ABOS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights • Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, to complete enrollment in the first half of 2025 • Expect to announce topline results of Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025 • Cash, cash equivalents and marketable securities of $258.9 million as of Sept. 30, 2024, expected t ...